• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Risankizumab induction therapy is effective for moderate-to-severe Crohn’s disease

byNeel MistryandTeddy Guo
June 7, 2022
in Chronic Disease, Gastroenterology, Rheumatology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. The risankizumab group showed greater clinical remission and endoscopic response rates compared to placebo across the ADVANCE and MOTIVATE trials.

2. Treatment-related adverse events were mild and comparable between the three groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Biologics are currently used as the first-line therapy for treatment of moderate-severe Crohn’s disease. However, a significant proportion of patients do not achieve adequate remission or have high rates of relapse despite biologics. It is believed that Risankizumab, an interleukin (IL)-23 inhibitor used to treat plaque psoriasis and psoriatic arthritis, may have a role in the treatment of active Crohn’s disease. However, current research in this regard is limited. This randomized controlled trial aimed to assess the safety and efficacy of risankizumab in patients with moderate-to-severe Crohn’s disease. Co-primary outcomes included clinical remission, as per the Crohn’s disease activity index (CDAI), and endoscopic response at 12 weeks from baseline. Key secondary outcomes included CDAI clinical response at weeks 4 and 12, as well as treatment-related adverse events. According to study results, risankizumab showed a greater clinical remission, compared to the controlled group, at various doses across the ADVANCE and MOTIVATE trials. Meanwhile, there were no significant differences in adverse events between the risankizumab and placebo groups. A major strength of this study is that it reported results from two simultaneous trials with a large sample size of patients from various centers, thus adding to the generalizability of the study.

Click to read the study in The Lancet

Relevant Reading: Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

In-depth [randomized-controlled trial]: Between May 10, 2017, and Aug 24, 2020 (ADVANCE trial), and Dec 18, 2017, and Sept 9, 2020 (MOTIVATE trial), 1578 patients and 988 patients were assessed for eligibility in 40 countries. Included were those between 16-80 years old with moderate-to-severe Crohn’s disease and resistance to one or more biologics. Altogether, 797 patients in the ADVANCE trial (320 in risankizumab 600 mg, 327 in risankizumab 1200 mg, and 150 in placebo) and 530 patients in the MOTIVATE trial (185 in risankizumab 600 mg, 184 in risankizumab 1200 mg, and 161 in placebo) were included. The primary outcome of CDAI clinical remission was greater in the intervention group compared to controlled, across both trials (ADVANCE: 45% with risankizumab 600 mg, 42% with risankizumab 1200 mg, 25% with placebo, p<0.0001; MOTIVATE: 42% with risankizumab 600 mg; 40% with risankizumab 1200 mg; 20% with placebo, p<0.0001). Similarly, this was the case for endoscopic response (ADVANCE: 40% with risankizumab 600 mg; 32% with risankizumab 1200 mg; 12% with placebo vs. MOTIVATE: 29% with risankizumab 600 mg; 34% with risankizumab 1200 mg; 11% with placebo). Majority of treatment-related adverse events were mild with one treatment-independent death in the risankizumab group. Overall, findings from this study suggest that risankizumab may be used as induction therapy in patients with Crohn’s disease.

RELATED REPORTS

ACKR1 variant increases risk of azathioprine-related hematopoietic toxicity

Ustekinumab and adalimumab comparable in safety and efficacy for treatment of Crohn’s disease

Gut microbiota signatures of long-term and short-term plant-based dietary pattern and cardiometabolic health

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: biologicCrohn's DiseaseGastroenterologyinflammatory bowel diseaseinflammatory bowel disease (IBD)rheumatologyrisankizumab
Previous Post

Monthly brolucizumab is noninferior to aflibercept in treating recalcitrant wet age-related macular degeneration

Next Post

Tranexamic acid decreases postoperative bleeding in non-cardiac surgery patients

RelatedReports

Nearly Half of All Pediatric Buprenorphine Exposures Result in Hospitalization
Chronic Disease

ACKR1 variant increases risk of azathioprine-related hematopoietic toxicity

June 30, 2022
Thalidomide may be effective in refractory pediatric Crohn’s disease
Chronic Disease

Ustekinumab and adalimumab comparable in safety and efficacy for treatment of Crohn’s disease

June 21, 2022
Provision of medically-tailored meals linked with lower admissions and medical spending
Chronic Disease

Gut microbiota signatures of long-term and short-term plant-based dietary pattern and cardiometabolic health

June 20, 2022
Elective colectomy associated with improved survival in ulcerative colitis
Chronic Disease

Upadacitinib significantly improves clinical remission rate for moderately to severely active ulcerative colitis

June 14, 2022
Next Post
Preoperative tumor embolization does not reduce operative blood loss

Tranexamic acid decreases postoperative bleeding in non-cardiac surgery patients

Combined MRI and NIH stroke scores may predict stroke prognosis

Viral meningitis can be differentiated from abusive head trauma with demographic, history, and clinical findings

Quick Take: Association of Visual Impairment With Economic Development Among Chinese Schoolchildren

No therapies for computer vision syndrome with high certainty evidence in meta-analysis

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Hybrid immunity protects against infection with omicron variant of COVID-19
  • #VisualAbstract: Tirzepatide Once Weekly for the Treatment of Obesity
  • Wellness Check: Sleep
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.